Basic Mirtazapine Information

• INN (International Nonproprietary Name): Mirtazapine.
• Brand Names Available In United Kingdom: Zispin and Mirtazapine Teva are commonly marketed in the UK and Ireland as orodispersible tablets in 15 mg, 30 mg and 45 mg strengths.
• ATC Code: N06AX11.
• Forms & Dosages: Tablets 7.5 mg (rare), 15 mg, 30 mg and 45 mg; orodispersible tablets 15 mg, 30 mg and 45 mg; oral solution exists but is not universally available.
• Manufacturers In United Kingdom: Originator Organon and multiple generic suppliers such as Teva, Sandoz, HEXAL, ratiopharm, Sun Pharma and Mylan supply mirtazapine to the UK market.
• Registration Status In United Kingdom: Approved by agencies including the MHRA and listed in national formularies for prescription use.
• OTC / Rx Classification: Prescription only (Rx) in the United Kingdom and other jurisdictions.

Key Findings From Recent Trials

Which recent studies matter to patients and prescribers asking about mirtazapine?

Major 2022–2025 studies and pooled analyses continue to support mirtazapine as an effective option for major depressive disorder, especially when insomnia or poor appetite are present.

Recent systematic reviews emphasise symptom‑domain benefits such as improved sleep and appetite rather than clear superiority over SSRIs on core mood rating scales.

Pragmatic trials often show similar overall response rates to comparator antidepressants when used in routine primary and secondary care settings.

UK prescribing audits from the last few years record steady use of mirtazapine in primary care, particularly where depression coexists with insomnia.

Regulatory indications remain aligned with national agencies such as the MHRA, EMA and FDA as reflected in product data and licensing records.

Main outcomes from cohorts frequently show early changes in sleep and appetite within one to two weeks.

Full antidepressant response is commonly observed by four to six weeks, consistent with standard treatment expectations.

Across practical settings, response rates to mirtazapine approximate those seen with other antidepressants when measured over standard treatment periods.

Safety observations across trials highlight pronounced somnolence, increased appetite and weight gain as the most consistent adverse effects.

Rare blood dyscrasias have been reported and warrant clinical vigilance if unexplained symptoms occur.

Elderly patients are more likely to experience sedation and orthostatic symptoms, and younger patients require specialist review when paediatric use is contemplated.

These findings align with regulatory dosing cautions for older adults and the absence of established paediatric safety data.

Clinical Mechanism Of Action

How does mirtazapine help with sleep, appetite and mood in plain terms?

Mirtazapine rebalances neurotransmitters that affect mood, appetite and sleep, so patients often notice improved sleep and appetite quickly while mood takes longer to improve.

Pharmacologically, mirtazapine is classed as a tetracyclic antidepressant with ATC code N06AX11.

Its principal actions include antagonism at central presynaptic α2‑adrenergic autoreceptors and heteroreceptors, which increases noradrenergic and serotonergic release.

It also blocks 5‑HT2 and 5‑HT3 receptors, resulting in relative enhancement of 5‑HT1A mediated neurotransmission and fewer gastrointestinal or sexual side effects compared with many SSRIs.

Potent H1 histamine antagonism explains the marked sedation and appetite stimulation commonly seen with mirtazapine.

Mirtazapine is extensively metabolised in the liver via multiple CYP pathways including CYP1A2, CYP2D6 and CYP3A4, so hepatic impairment requires cautious dose selection and slow titration.

Scope Of Approved And Off-Label Use

What is mirtazapine licensed for in the UK and how do clinicians use it off label?

In the United Kingdom mirtazapine is licensed for the treatment of major depressive disorder and is prescription only through the MHRA regulatory framework.

Common UK formulations include orodispersible tablets in 15 mg, 30 mg and 45 mg strengths marketed under brands such as Zispin and Mirtazapine Teva.

Standard adult dosing for MDD is 15–45 mg once daily at bedtime.

Clinicians often use mirtazapine off label for insomnia when it is associated with depression, commonly at lower nocturnal doses to encourage sleep without excessive daytime sedation.

Mirtazapine is also employed off label as an appetite stimulant in palliative or oncology settings, typically starting at 15 mg nocte and adjusting according to clinical benefit.

Less commonly, it may be considered for refractory nausea or for anxiety comorbid with depression, although evidence is more limited for these indications.

Prescribing for adolescents is cautious because safety and efficacy are not established in children and specialist review is advised before any off‑label initiation.

Dosage Strategy

What starting dose should a patient expect and how is mirtazapine adjusted?

The typical adult regimen is 15–45 mg once daily at night, with many prescribers starting at 15 mg and titrating up as needed.

Lower initial doses such as 7.5–15 mg may be used when a sedative effect is desired or to reduce adverse effects during initiation.

For major depressive disorder, standard practice is to start at 15 mg at bedtime and reassess after one to two weeks, increasing to 30 mg and then 45 mg if response is inadequate and tolerability permits.

When mirtazapine is used primarily for insomnia or comorbid anxiety, clinicians often choose nocturnal doses in the 7.5–15 mg range to balance sleep benefit with daytime function.

In palliative care for appetite stimulation, 15 mg nocte is a common starting point with titration guided by appetite and weight response.

Special population rules apply: elderly patients should start at 7.5–15 mg and titrate cautiously to reduce falls and orthostatic hypotension.

In hepatic impairment, begin at the lowest dose and titrate slowly because active drug levels may be increased.

Renal impairment requires clinical caution in severe cases, although mild to moderate impairment often follows standard adult dosing with monitoring.

Expect early symptomatic changes such as sleep or appetite within one to two weeks and a full antidepressant response by four to six weeks.

Treatment for depression is usually continued for six to twelve months after remission to reduce relapse risk, and gradual tapering is recommended to minimise withdrawal effects.

Safety Protocols

What checks and precautions should prescribers and pharmacists follow before and during treatment?

Absolute contraindications include known hypersensitivity to mirtazapine or excipients and concurrent use with monoamine oxidase inhibitors or within 14 days of discontinuing an MAOI.

Relative caution is recommended in severe hepatic or renal impairment, bipolar disorder, seizure history, recent myocardial infarction, glaucoma, prostatic hypertrophy and in elderly patients.

Common adverse effects (observed in at least 1% of patients) include somnolence, increased appetite and weight gain, dry mouth, dizziness, constipation and fatigue.

Less common reactions (0.1–1%) include peripheral oedema, vivid dreams and rare blood dyscrasias, which may prompt a full blood count if clinically indicated.

Transaminase elevations have been reported rarely; consider baseline hepatic history and check LFTs if symptoms suggest hepatic injury.

Baseline assessment should record weight, blood pressure, liver and renal history, concomitant medications and suicide risk before initiation.

Advise caution with driving and operating machinery until sedation and tolerance are established.

Interaction Mapping

Which substances and medicines interact importantly with mirtazapine?

Alcohol markedly increases central nervous system depression and sedation, so patients should be advised to avoid or limit alcohol, particularly during initiation and dose changes.

There are no special dietary restrictions for absorption, but counsel patients about appetite increases and potential weight gain from greater food intake.

Concurrent administration with MAOIs is contraindicated and a 14‑day washout period is required when switching to or from an MAOI.

Combining mirtazapine with other serotonergic agents should be approached with caution because of the risk of serotonin syndrome; watch for agitation, hyperreflexia and hyperthermia.

Concomitant use of sedatives, opioids and benzodiazepines can cause additive sedation and increase the risk of respiratory depression.

Anticholinergic drugs add to anticholinergic burden and may worsen urinary retention or precipitate angle‑closure glaucoma in susceptible patients.

Mirtazapine is metabolised through CYP pathways including CYP1A2, CYP2D6 and CYP3A4, so strong inhibitors or inducers of these enzymes can alter mirtazapine exposure and require clinical monitoring and dose adjustment where appropriate.

In overdose, expect central nervous system depression, tachycardia, possible cardiac conduction abnormalities and seizures; emergency medical review is required.

Patient Experience Analysis

What do patients commonly notice first, and what complaints should clinicians expect?

Survey data from UK primary care indicate that improved sleep and appetite are the earliest perceived benefits, often within one to two weeks of starting mirtazapine.

Mood improvements generally follow, with many patients reporting meaningful change by four to six weeks.

Discontinuation is most commonly driven by daytime sedation and weight gain rather than sexual dysfunction, which tends to be less frequent than with many SSRIs.

Online forums and peer support groups reflect similar themes: positive feedback for insomnia and appetite restoration, and negative feedback about weight gain and persistent drowsiness.

Patients often prefer orodispersible formulations for ease of use, particularly those with swallowing difficulties or who value a tablet that dissolves.

Clinicians should discuss patient priorities, for example whether sleep benefit outweighs the potential for weight gain, as part of shared decision‑making.

Distribution And Pricing Landscape

Who supplies mirtazapine and how does pricing affect access in the UK?

Mirtazapine is manufactured globally by Organon as the originator and by multiple generics including Teva, Sandoz, HEXAL, ratiopharm, Sun Pharma and Mylan.

The UK market commonly includes Zispin and a variety of generic orodispersible and film‑coated tablets in 15 mg, 30 mg and 45 mg strengths.

NHS prescribing typically favours generics where suitable, which substantially reduces medication costs for the health service and patients.

Private prescription prices vary by pack size and pharmacy, and generics remain the cost‑effective option for most long‑term prescribing.

Supply is routinely available but intermittent shortages can occur in multi‑supplier markets, so pharmacists should check brand and formulation availability if a patient requests a specific tablet type.

In our online pharmacy, mirtazapine is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Alternative Options

How does mirtazapine compare with other antidepressants and when might alternatives be chosen?

SSRIs such as sertraline, escitalopram and fluoxetine are broadly first‑line for major depressive disorder, and they tend to be less sedating and cause less weight gain but more sexual dysfunction than mirtazapine.

SNRIs including venlafaxine and duloxetine are useful where depression coexists with chronic pain syndromes, though venlafaxine can increase blood pressure at higher doses.

Other atypical antidepressants include trazodone, which shares sedative utility, and bupropion, which is activating and associated with lower risk of sexual side effects and weight gain.

Mirtazapine’s pros are rapid sleep benefit, appetite stimulation and relatively low rates of sexual dysfunction.

Its cons include sedation, weight gain and potential orthostatic hypotension, as well as rare haematological events requiring vigilance.

Choice of antidepressant should be symptom driven: mirtazapine is often preferred when insomnia or loss of appetite is prominent, while activating agents may be better if fatigue and low energy are predominant.

Regulatory Status

What is the official classification and where is mirtazapine approved?

Mirtazapine carries ATC code N06AX11 and is classified among the tetracyclic antidepressants in the ATC system.

It is approved by major regulatory bodies including the MHRA in the United Kingdom, the EMA in Europe, the FDA in the United States and the TGA in Australia.

The product is marketed internationally under various brands including Remeron in North America, Zispin and Mirtazapine Teva in the UK and Ireland, and Avanza in Australia and New Zealand.

Formulations licensed across markets include tablets and orodispersible tablets in 15 mg, 30 mg and 45 mg strengths; a 7.5 mg tablet exists in some territories but is uncommon.

National formularies such as NHS lists typically favour generic mirtazapine preparations for management of MDD in adults.

Consolidated FAQ

What are the questions patients ask most about mirtazapine?

Q: How long before mirtazapine works?

A: Sleep and appetite changes may be noticed within one to two weeks, while mood response is often apparent by four to six weeks.

Q: Can I drive on mirtazapine?

A: Avoid driving and operating heavy machinery until you know how sedation affects you.

Q: Is mirtazapine safe in pregnancy or breastfeeding?

A: Use only if the expected clinical benefit justifies the potential risk to the fetus or infant and consult a specialist for personalised advice.

Q: Any precautions when switching from an SSRI?

A: Monitor for serotonin syndrome and consider cross‑taper strategies with specialist input when changing antidepressant classes.

Q: What about overdose?

A: Overdose can lead to serious CNS depression, tachycardia, cardiac conduction abnormalities and seizures and requires immediate emergency care.

Q: Can children take it?

A: Not routinely; safety and efficacy in children and adolescents are not established and specialist review is required for off‑label use.

Q: How should I stop mirtazapine?

A: Taper gradually under clinical supervision to reduce the risk of withdrawal symptoms and relapse.

Visual Guide

What visuals help patients and clinicians understand mirtazapine quickly?

Recommended visuals include a receptor map showing α2, 5‑HT2/3 and H1 antagonism with captions linking each receptor action to clinical effects such as sedation, appetite increase and lower sexual side effects.

A titration flowchart is useful, for example: start 15 mg → assess at 1–2 weeks → increase to 30–45 mg if needed, with special boxes for elderly and hepatic impairment recommending 7.5–15 mg starts.

A side‑effect frequency bar chart visually highlighting somnolence, weight gain, dry mouth, dizziness and constipation is helpful for shared decision‑making.

Images of UK formulations such as orodispersible tablets in 15, 30 and 45 mg strengths under brands like Zispin and Mirtazapine Teva support patient recognition and adherence.

A quick‑reference checklist for prescribers summarising contraindications, baseline checks and monitoring schedule aids safe prescribing in primary care.

Each visual should include accessible captions and source notes referencing MHRA or NHS product data where applicable.

Storage And Transport

How should pharmacies and patients store and transport mirtazapine?

Store mirtazapine between 15–30°C and avoid moisture and direct light to protect tablet integrity.

Keep tablets in the original packaging until use and ensure they are stored out of the reach of children.

No refrigeration or special transport conditions are required for finished formulations under licensed packing.

Orodispersible tablets must be kept dry until use and patients should be instructed to place the tablet on the tongue and allow it to dissolve rather than chewing unless the product information states otherwise.

Pharmacies should include dispensing labels highlighting the risk of sedation and the appropriate storage temperature when handing out mirtazapine.

Guidelines For Proper Use

What baseline checks and follow‑up steps should UK prescribers follow when starting mirtazapine?

Baseline assessment should confirm a diagnosis of major depressive disorder and record weight, blood pressure, hepatic and renal history, current medications, pregnancy status and suicide risk.

Initiate treatment at 15 mg nocte for adults and consider 7.5–15 mg for elderly patients, while discussing sedation, weight gain, alcohol avoidance and driving precautions with the patient.

Review response at one to two weeks focusing on sleep and appetite, and reassess antidepressant effect at four to six weeks to decide on titration to 30–45 mg if required.

Monitor weight and metabolic indicators, check liver function if clinically indicated and order a full blood count if symptoms suggest possible haematological effects.

When switching from MAOIs, ensure a 14‑day washout period and seek specialist advice for complex medication changes or for paediatric cases.

On discontinuation, taper gradually to lessen withdrawal risk and document shared decision‑making, counselling and follow‑up plans in clinical records.

Delivery Across United Kingdom

Closing Notes For Clinicians And Patients

Mirtazapine is a well‑established option for adults with major depressive disorder where insomnia or appetite loss are prominent symptoms.

Choice of antidepressant should reflect the patient’s symptom priorities and tolerability profile, with careful baseline assessment and follow‑up.

Pharmacists should verify formulation and brand preferences, advise on storage and sedation risks and report supply issues promptly to prescribers.

Always document shared decision‑making and discuss realistic timelines for symptom improvement so patients know what to expect.

Where specialist issues arise, such as paediatric prescribing, severe hepatic impairment or complex drug interactions, seek specialist input before initiating therapy.